NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against ...

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...

United States Anxiety Disorders and Depression Treatment Market Research Report 2025-2033: Developments in Medicinal Therapies, and Raising Awareness of Mental …

The United States Anxiety Disorders and Depression Treatment Market is projected to grow from USD 6.17 billion in 2024 to USD ...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
Nature

Medicinal Chemistry Approaches for Small-Molecule Drug Discovery

The goal of a small-molecule drug discovery campaign is the development of chemical entities that fulfil the criteria of the target product profile for progression into clinical trials. This objective ...